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Introduction
A remarkable, albeit unexplained, feature of genes impli-
cated in familial breast cancer is their apparent function
within a cellular pathway designed to monitor and repair
damage to DNA. BRCA1 and BRCA2 are thought to be
components of the cellular machinery involved in the repair
of chromosomal breaks through homologous recombina-
tion.  TP53, the quintessential tumour suppressor gene,
regulates an essential checkpoint that is activated in
response to DNA damage and mediates both cell cycle
arrest and apoptosis. Whereas the breast cancer risk
associated with mutations in BRCA1 or  BRCA2 far
exceeds the risk for other types of cancer (e.g. ovarian
cancer and pancreatic cancer), germline mutations in
TP53 confer a high degree of susceptibility to many types
of cancer, including breast cancer, bone and soft-tissue
sarcomas, brain and adrenocortical tumours — so-called
Li–Fraumeni Syndrome (LFS).
Strict clinical definitions have been established for the clas-
sical form of LFS [1] and for a broader Li–Fraumeni-like
syndrome [2]. Germline mutations in TP53 are present in
around 80% of families with LFS and in 40% of those with
Li–Fraumeni-like syndrome [3]. The genetic lesion in fami-
lies lacking abnormalities in TP53 is unknown, but the mul-
tiple cases of rare cancers arising at early ages makes it
highly unlikely that these result from a chance aggregation.
Efforts at identifying subtle alterations in TP53 gene regu-
latory sequences have been unsuccessful, as has been
the screening of many candidate tumour suppressor
genes, including PTEN,  p16,  MDM2,  bcl10,  p63 and
hChk1 (for a recent review, see [3]). A classic LFS family
with wild-type TP53, however, was found to harbour a
mutation in the cell cycle checkpoint kinase hCHK2,
which segregated with cancer susceptibility and demon-
strated somatic loss of heterozygosity [4,5]. The mutation
1100delC results in a frameshift within the kinase catalytic
domain, and encodes a nonfunctional protein [6].
The hCHK2 1100delC mutation: a high-
penetrance or low-penetrance predisposition
gene?
hCHK2 was initially identified as a potential tumour sup-
pressor gene by virtue of its function within the DNA
damage checkpoint in the yeast strain Schizosaccha-
romyces pombe. The yeast ortholog, Cds1, is activated by
the ortholog of the ataxia-telangiectasia mutated (ATM)
protein, Rad3, and in turn phosphorylates Cdc25, trigger-
ing a G2/M cell cycle arrest. In mammalian cells, however,
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the functional pathway appears more complex. hCHK2 is
phosphorylated by ATM following DNA damage, but its
phosphorylation targets include CDC25A, CDC25C, p53,
and BRCA1 (for reviews, see [7,8]). hCHK2 therefore
functions at a critical intersection of cellular pathways
involved in the response to DNA damage.
The clinical spectrum of cancers associated with germline
hCHK2 mutations may reflect their relative contribution
toward the function of p53 and/or BRCA1. A small number
of hCHK2 mutations have now been identified in families
with either LFS or Li–Fraumeni-like syndrome. These
include the frameshift 1100delC [4,9] and the missense
mutation R145W, which encodes a grossly unstable
protein [5]. Another missense mutation, I157T, is of uncer-
tain significance, since it exhibits defective in vitro phos-
phorylation of CDC25A and BRCA1 [10], yet it is present
in 2–6% of the Finnish population where it appears to be
associated with only a small, if any, increase in cancer risk.
While the hCHK2 1100delC mutation clearly encodes a
nonfunctional protein, the tumour spectrum initially
reported with this germline mutation ranges from classic
LFS [4] to atypical Li–Fraumeni-like syndrome, with a pre-
dominance of early-onset breast cancer [9]. Most recently,
population-based analyses have demonstrated that this
specific mutation is present in approximately 1% of the
population and that it confers a moderately increased risk
for breast cancer [9].
An international consortium undertaking a genome-wide
linkage analysis in breast cancer families lacking
BRCA1/BRCA2 mutations identified one large family in
which a complex pattern of inheritance of cancer suscepti-
bility pointed to the hCHK2 gene on chromosome 22. A
number of individuals within this pedigree (but not all) who
had breast and some other cancers were found to harbour
the 1100delC mutation. The consortium went on to under-
take a large-scale population study of control individuals
(n=1620), of individuals with breast cancer unselected
for family history (n=636), of cases from families with a
family history but no BRCA1/BRCA2 mutation (n=1071)
and of cases from BRCA1/BRCA2 families (n=520). The
hCHK2 1100delC mutation was present in 1.1% of the
control group and in 1.4% of breast cancer cases unse-
lected for family history. In familial cases of breast cancer
lacking a BRCA1/BRCA2 mutation, however, the fre-
quency of the hCHK2 1100delC mutation was signifi-
cantly elevated, at 5.1% (P=0.00000003). In families
with the highest risk factors (identified by an increasing
number of female breast cancer or a case of male breast
cancer), the frequency was as high as 13.5% [11]. The
authors calculated the risk conferred by the hCHK2
1100delC variant as 1.7 in females and as 10.28 in males
(under a simple model where hCHK2 and other genes
combine multiplicatively), and determined that around 1%
of female breast cancer and 9% of male breast cancer is
attributable to the hCHK2 1100delC variant. Finally, the
observation that the prevalence of the hCHK2 1100delC
mutation was only 1% in familial cases known to carry
mutations in BRCA1 led the authors to postulate that
inactivation of these two genes may be functionally redun-
dant, consistent with the known phosphorylation of
BRCA1 by hCHK2 following DNA damage.
These observations were supported by a Finnish popula-
tion-based study, which reported a population frequency
of the hCHK2 1100delC mutation of 1.4%, compared
with a prevalence of 2.0% in sporadic breast cancer
cases (odds ratio=1.48, P=0.182), and reported a fre-
quency of 3.1% in one cohort of familial cases (odds
ratio=2.27, P=0.021) and of 5.5% in a second indepen-
dent cohort of familial breast cancer (odds ratio=4.2,
P=0.0002) [12].
Taken together, these population-based studies indicate
that hCHK2 1100delC is a relatively common mutation in
the population, which functions as a low-penetrance sus-
ceptibility gene for breast cancer [11,12].
Unanswered questions
These studies leave a number of unanswered questions.
Does the hCHK2 1100delC mutation confer an increased
risk for different tumours in addition to breast cancer, and
how can we reconcile its low-penetrant phenotype based
on population studies with its initial discovery in the highly
penetrant LFS?
One possible explanation is selection bias in the analysis
of cancer pedigrees. As amply demonstrated for
BRCA1/BRCA2 mutations, the cancer risk derived from
analyses of cancer kindreds is exaggerated by virtue of
selection criteria aimed at collecting families in which most
mutation carriers have developed breast cancer. A second
explanation invokes the contribution of modifier genes,
additional genetic variants in the population that may mod-
ulate the effect of hCHK2 mutations in different families.
Whether one or both of these explanations contribute to
the different phenotypes reported for the hCHK2
1100delC mutation, it remains possible that this mutation
does confer an increased risk for tumours in addition to
breast cancer, such as LFS-associated cancers that
demonstrate somatic loss of heterozygosity. However, no
statistically significant increase in risk for other tumours
was noted in a population-based study [11].
Further definition of the cellular hCHK2 pathway (i.e. the
relative physiological significance of its phosphorylation of
p53 versus BRCA1) will also help clarify its place in the
pantheon of tumour suppressor genes. What then should
clinicians say to women with familial breast cancer who
are found to harbour the hCHK2 1100delC mutation?125
Guidelines for genetic counselling in patients with low-
penetrant mutations are not well established, and in some
ways may be akin to recommendations for women who are
found to have precursor lesions following an abnormal
mammogram and are at moderate risk for developing
breast cancer. The optimal timing and frequency of
screening mammography and the potential utility of anti-
oestrogenic chemoprevention in carriers of the hCHK2
1100delC mutation remain to be determined.
Competing interests
None declared.
Referencess
1. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker
MA, Miller RW: A cancer family syndrome in twenty-four kin-
dreds. Cancer Res 1988, 48:5358-5362.
2. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM,
Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW,
Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell
ELD, Santibanez-Koref MF: Prevalence and diversity of consti-
tutional mutations in the p53 gene among 21 Li–Fraumeni
families. Cancer Res 1994, 54:1298-1304.
3. Varley JM: Germline  TP53 mutations and Li–Fraumeni Syn-
drome. Mut Res 2003, in press.
4. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon
KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch
JM, Li FP, Garber JE, Haber DA: Heterozygous germ line
hCHK2 mutations in Li–Fraumeni Syndrome. Science 1999,
286:2528-2531.
5. Lee SB, Kim SH, Bell DW, Wahrer DCR, Schiripo TA, Jorczak
MM, Sgroi D, Garber JE, Li FP, Nichols KE, Varley JM, Godwin
AK, Shannon KE, Harlow E, Haber DA: Destabilization of CHK2
by a missense mutation associated with Li–Fraumeni Syn-
drome. Cancer Res 2001, 61:8062-8067.
6. Wu X, Webster SR, Chen J: Characterization of tumor-associ-
ated Chk2 mutations. J Biol Chem 2001, 276:2971-2974.
7. Rhind N, Russell P: Chk1 and Cds1: linchpins of the DNA
damage and replication checkpoint pathways. J Cell Sci 2000,
113:3889-3896.
8. Zhou B-BS, Elledge SJ: The DNA damage response: putting
checkpoints into perspective. Nature 2000, 408:433-439.
9. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aalto-
nen LA, Blomqvist C, Aittomaki K, Nevanlinna H: p53, CHK2, and
CHK1 genes in Finnish families with Li–Fraumeni Syndrome:
further evidence of CHK2 in inherited cancer predisposition.
Cancer Res 2001, 61:5718-5722.
10. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The
ATM–Chk2–Cdc25A checkpoint pathway guards against
radioresistant DNA synthesis. Nature 2001, 410:842-847.
11. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M,
de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van
Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers
C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N,
Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R,
Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J,
Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA,
Nathanson KL, Weber B, Rahman N, Stratton MR: Low-pene-
trance susceptibility to breast cancer due to CHEK2*1100delC
in noncarriers of BRCA1 or  BRCA2 mutations. Nat Genet
2002, 31:3-4.
12. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara
O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K,
Blomqvist C, Bartek J, Kallioniemi O-P, Nevanlinna H: A CHEK2
genetic variant contributing to a substantial fraction of familial
breast cancer. Am J Hum Genet 2002, 71:432-438.
Correspondence
Jenny Varley, CR-UK Department of Cancer Genetics, Paterson Insti-
tute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK.
Tel: +44 (0)161 446 3062; fax: +44 (0)161 446 3109; e-mail:
jvarley@picr.man.ac.uk
Available online http://breast-cancer-research.com/content/5/3/123